L-Carnitine
Amino-acid derivative that shuttles fat into cells to be burned for energy.
What is L-Carnitine?
L-Carnitine is a performance supplement used for modest weight & bmi reduction. NutriDex grades the human evidence as Moderate. L-carnitine is a compound the body makes from lysine and methionine (and gets from red meat) that ferries fatty acids into mitochondria to be burned for energy. Across many randomized trials it produces small, consistent effects rather than dramatic ones: a meta-analysis of 37 RCTs found ~1.2 kg average weight loss (best near 2 g/day), and trials in type 2 diabetes show modest drops in HbA1c (~0.16% per gram/day) and fasting glucose. In non-alcoholic fatty liver disease it lowers ALT and AST, and in exercise it reduces post-workout muscle soreness and damage markers. Heart-failure and post-heart-attack trials report improved ejection fraction and, in older pooled data, lower mortality—though those trials are small and dated. Effects are real but modest, heterogeneous, and not in major guidelines. A caveat: gut bacteria turn carnitine into TMAO, a metabolite linked to atherosclerosis.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Body weight & BMI reductionMeta-analysis of 37 RCTs found ~1.2 kg loss (best near 2 g/day); real but modest and not guideline-endorsed. | Moderate | ↑ benefit · small | 1 |
| Glycemic control in type 2 diabetesDose-response meta-analysis: ~0.16% HbA1c drop per g/day, but high heterogeneity limits certainty. | Moderate | ↑ benefit · small | 1 |
| Liver enzymes in NAFLD (ALT/AST)8-RCT meta-analysis showed sizable ALT/AST reductions but was rated low-certainty evidence. | Preliminary | ↑ benefit · moderate | 1 |
| Post-exercise muscle soreness & damageMeta-analysis plus systematic review support reduced soreness/CK; performance effects remain inconsistent. | Moderate | ↑ benefit · small | 2 |
| Cardiac function & mortality after heart eventsPooled trials raised LVEF ~4% and showed lower post-MI mortality, but trials are small, old and pre-guideline. | Preliminary | ↑ benefit · moderate | 2 |
| TMAO / atherosclerosis riskGut microbes convert carnitine to TMAO, linked to CV events in humans and atherosclerosis in mice. | Preliminary | ⚠ risk | 1 |